Editors
Douglas B. Cines, David J. Kuter, Adrian C. Newland, Drew Provan, John W. Semple
ESH and the editors wish to thank Dr Diana Samson for her essential contribution to the production of this handbook.
Douglas B. Cines, David J. Kuter, Adrian C. Newland, Drew Provan, John W. Semple
ESH and the editors wish to thank Dr Diana Samson for her essential contribution to the production of this handbook.
Editor: John W. Semple | Contributors: A.S. Weyrich, K. Yazdanbakhsh, J.W. Semple, S.J. Urbaniak
In this section, the basic science of ITP is reviewed. This includes discussion of megakaryocyte differentiation and platelet production as well as a review of autoimmune mechanisms and T regulatory cell disturbances in ITP. Mouse models of ITP that explain the concepts of increased platelet destruction and inhibition of platelet production are then explored along with the possible utility of peptide therapy directed at GPIIb/IIIa on the platelet membrane.
Editor: Douglas B. Cines | Contributors: D.B. Cines, A. Sarpatwari, H. Wadenvik, D.J. Kuter
This section assesses the clinical dilemmas in ITP. After reviewing the pathophysiology of ITP, studies using Indium labelled platelets are reviewed to see if they can predict the response to splenectomy. This section is concluded with a discussion of the recent international guidelines for the treatment of ITP.
Editor: David J. Kuter | Contributors: D.J. Kuter, M. Michel, A. Lazarus
This section reviews new and novel approaches to treating ITP. The biochemistry and biology of the new TPO mimetics (eltrombopag and romiplostim) is presented along with a complete review of the clinical studies of these agents in ITP. The biology and clinical studies with another novel ITP therapy, rituximab, are then explored in detail. The final topic in this section explores the unique and evolving biology of how Fc receptor therapies work in ITP.
Editor: Douglas B. Cines | Contributors: R. Clynes, B. Olsson, A.C. Newland
This section explores future approaches to the treatment of ITP. Further investigations of Fc receptors and how they might be further targeted for therapy is presented along with the prospect that regulatory antibodies might also be exploited in treatment. The participation of cytotoxic T-lymphocytes in ITP is discussed and the section concluded by a discussion of how these future approaches might lead to better understanding and treatment of ITP.